$1.15
Live
1.74%
Downside
Day's Volatility :2.59%
Upside
0.86%
13.9%
Downside
52 Weeks Volatility :33.99%
Upside
23.33%
Period | Enzo Biochem Inc | Index (Russel 2000) |
---|---|---|
3 Months | -1.71% | 0.0% |
6 Months | 5.5% | 0.0% |
1 Year | -16.06% | 0.0% |
3 Years | -64.83% | -23.0% |
Market Capitalization | 58.1M |
Book Value | $1.35 |
Earnings Per Share (EPS) | -0.35 |
PEG Ratio | 0.0 |
Wall Street Target Price | 5.5 |
Profit Margin | 134.17% |
Operating Margin TTM | -25.47% |
Return On Assets TTM | -12.77% |
Return On Equity TTM | -39.9% |
Revenue TTM | 33.3M |
Revenue Per Share TTM | 0.66 |
Quarterly Revenue Growth YOY | 7.199999999999999% |
Gross Profit TTM | 11.6M |
EBITDA | -15.4M |
Diluted Eps TTM | -0.35 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 378.26%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 104.7M | ↓ 2.87% |
Net Income | -10.3M | ↑ 312.18% |
Net Profit Margin | -9.86% | ↓ 7.54% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 81.2M | ↓ 22.48% |
Net Income | -98.8M | ↑ 857.09% |
Net Profit Margin | -121.7% | ↓ 111.84% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 76.0M | ↓ 6.34% |
Net Income | -33.9M | ↓ 65.69% |
Net Profit Margin | -44.58% | ↑ 77.12% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 117.7M | ↑ 54.87% |
Net Income | 3.4M | ↓ 110.11% |
Net Profit Margin | 2.91% | ↑ 47.49% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 107.1M | ↓ 9.05% |
Net Income | -22.6M | ↓ 759.21% |
Net Profit Margin | -21.09% | ↓ 24.0% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 31.1M | ↓ 70.99% |
Net Income | 20.3M | ↓ 189.86% |
Net Profit Margin | 65.32% | ↑ 86.41% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 16.3M | ↓ 10.6% |
Net Income | -10.7M | ↓ 14.26% |
Net Profit Margin | -65.22% | ↑ 2.78% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 16.1M | ↓ 1.41% |
Net Income | -14.7M | ↑ 38.22% |
Net Profit Margin | -91.44% | ↓ 26.22% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 31.1M | ↑ 92.84% |
Net Income | 20.3M | ↓ 237.74% |
Net Profit Margin | 65.32% | ↑ 156.76% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 7.8M | ↓ 74.87% |
Net Income | -6.6M | ↓ 132.61% |
Net Profit Margin | -84.76% | ↓ 150.08% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 8.6M | ↑ 9.57% |
Net Income | -3.1M | ↓ 53.73% |
Net Profit Margin | -35.79% | ↑ 48.97% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 8.0M | ↓ 6.21% |
Net Income | -3.0M | ↓ 1.34% |
Net Profit Margin | -37.65% | ↓ 1.86% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 101.7M | ↓ 5.58% |
Total Liabilities | 20.5M | ↑ 9.29% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 106.6M | ↑ 4.9% |
Total Liabilities | 20.6M | ↑ 0.36% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 112.5M | ↑ 5.53% |
Total Liabilities | 54.2M | ↑ 162.75% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 113.7M | ↑ 1.02% |
Total Liabilities | 45.1M | ↓ 16.71% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 95.9M | ↓ 15.69% |
Total Liabilities | 41.4M | ↓ 8.23% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 121.9M | ↑ 27.15% |
Total Liabilities | 43.4M | ↑ 4.89% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 76.5M | ↓ 10.27% |
Total Liabilities | 43.6M | ↑ 8.49% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 72.1M | ↓ 5.74% |
Total Liabilities | 53.1M | ↑ 21.8% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 121.9M | ↑ 69.13% |
Total Liabilities | 43.4M | ↓ 18.28% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 106.3M | ↓ 12.78% |
Total Liabilities | 32.0M | ↓ 26.22% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 99.1M | ↓ 6.8% |
Total Liabilities | 28.3M | ↓ 11.65% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 93.5M | ↓ 5.66% |
Total Liabilities | 24.4M | ↓ 13.65% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -2.7M | ↑ 1234.15% |
Investing Cash Flow | -1.9M | ↑ 11.15% |
Financing Cash Flow | 559.0K | ↓ 133.49% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 4.8M | ↓ 275.72% |
Investing Cash Flow | -8.1M | ↑ 318.0% |
Financing Cash Flow | 4.2M | ↑ 650.09% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -17.2M | ↓ 457.45% |
Investing Cash Flow | -2.2M | ↓ 73.3% |
Financing Cash Flow | 7.0M | ↑ 66.97% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 387.0K | ↓ 102.25% |
Investing Cash Flow | -34.5M | ↑ 1489.72% |
Financing Cash Flow | -242.0K | ↓ 103.46% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -16.6M | ↓ 4386.82% |
Investing Cash Flow | 25.2M | ↓ 173.12% |
Financing Cash Flow | -241.0K | ↓ 0.41% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -37.0M | ↑ 122.88% |
Investing Cash Flow | 99.0M | ↑ 292.42% |
Financing Cash Flow | -1.1M | ↑ 366.8% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -6.2M | ↓ 28.7% |
Investing Cash Flow | -869.0K | ↑ 33.28% |
Financing Cash Flow | -62.0K | ↓ 34.74% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -5.1M | ↓ 18.46% |
Investing Cash Flow | -666.0K | ↓ 23.36% |
Financing Cash Flow | 3.3M | ↓ 5377.42% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -13.4M | ↑ 164.62% |
Investing Cash Flow | -254.0K | ↓ 61.86% |
Financing Cash Flow | -518.0K | ↓ 115.83% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -13.4M | ↑ 0.0% |
Investing Cash Flow | -254.0K | ↑ 0.0% |
Financing Cash Flow | -518.0K | ↑ 0.0% |
Sell
Neutral
Buy
Enzo Biochem Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Enzo Biochem Inc | -0.86% | 5.5% | -16.06% | -64.83% | -64.17% |
Idexx Laboratories, Inc. | -9.83% | -4.55% | 7.02% | -29.06% | 64.14% |
Agilent Technologies Inc. | -0.69% | 3.67% | 26.97% | -11.54% | 83.93% |
Thermo Fisher Scientific, Inc. | -1.42% | 9.73% | 30.29% | -1.1% | 112.21% |
Danaher Corp. | 0.45% | 16.22% | 34.47% | -11.7% | 98.5% |
Iqvia Holdings Inc. | -1.68% | 2.31% | 28.84% | -7.12% | 65.36% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Enzo Biochem Inc | NA | NA | 0.0 | 0.0 | -0.4 | -0.13 | NA | 1.35 |
Idexx Laboratories, Inc. | 45.68 | 45.68 | 4.88 | 10.56 | 0.63 | 0.23 | NA | 19.16 |
Agilent Technologies Inc. | 28.86 | 28.86 | 2.97 | 5.24 | 0.25 | 0.08 | 0.01 | 20.53 |
Thermo Fisher Scientific, Inc. | 37.11 | 37.11 | 2.24 | 21.72 | 0.14 | 0.05 | 0.0 | 124.17 |
Danaher Corp. | 50.0 | 50.0 | 2.65 | 7.58 | 0.08 | 0.04 | 0.0 | 68.92 |
Iqvia Holdings Inc. | 30.78 | 30.78 | 1.16 | 11.19 | 0.23 | 0.05 | NA | 36.83 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Enzo Biochem Inc | Buy | $58.1M | -64.17% | NA | 134.17% |
Idexx Laboratories, Inc. | Buy | $37.9B | 64.14% | 45.68 | 22.34% |
Agilent Technologies Inc. | Buy | $39.9B | 83.93% | 28.86 | 21.75% |
Thermo Fisher Scientific, Inc. | Buy | $228.9B | 112.21% | 37.11 | 14.69% |
Danaher Corp. | Buy | $196.4B | 98.5% | 50.0 | 17.83% |
Iqvia Holdings Inc. | Buy | $43.1B | 65.36% | 30.78 | 9.39% |
Insights on Enzo Biochem Inc
Revenue is down for the last 2 quarters, 8.55M → 8.02M (in $), with an average decrease of 6.2% per quarter
Netprofit is up for the last 3 quarters, -6.61M → -3.02M (in $), with an average increase of 58.8% per quarter
In the last 1 year, Danaher Corp. has given 33.3% return, outperforming this stock by 51.2%
In the last 3 years, Enzo Biochem Inc has experienced a drawdown of -64.8%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 53.1%
Harbert Fund Advisors Inc
Renaissance Technologies Corp
Vanguard Group Inc
BlackRock Inc
Geode Capital Management, LLC
Dimensional Fund Advisors, Inc.
enzo biochem inc is a financial services company located in 60 executive blvd, farmingdale, new york, united states.
Organization | Enzo Biochem Inc |
Employees | 179 |
CEO | Ms. Kara Cannon |
Industry | Health Technology |
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$1.15
+0.0%
Invesco Bulletshares 2025 Hi
$1.15
+0.0%
Schwab International Dividend Equity Etf
$1.15
+0.0%
Blockchain Coinvestors Acquisition Corp.
$1.15
+0.0%
Allgiant Travel Company
$1.15
+0.0%
Rogers Corp
$1.15
+0.0%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$1.15
+0.0%
Iheartmedia
$1.15
+0.0%
Lightpath Technologies Inc
$1.15
+0.0%